A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs Avelumab (Primary) ; Defactinib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Verastem
- 26 Jan 2017 According to a Verastem media release, first patient has been dosed in this study.
- 22 Mar 2016 According to a Verastem Inc. media release, the company will present scientific data at the Society of Gynecologic Oncology 2016 Annual Meeting on Women Cancer.
- 07 Mar 2016 New trial record